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This is a multicenter retrospective comparison of 2 myeloablative conditioning regimens in 454 patients with
acute myeloid leukemia (AML) in remission: busulfan (4 days) and fludarabine (BUFLU) versus thiotepa, busulfan,
and fludarabine (TBF). Eligible for this study were patients allografted between January 2008 and December 2018
in 10 transplant centers, with AML in first or second remission: 201 patients received BUFLU, whereas 253
received TBF. The 2 groups (BUFLU and TBF) were comparable for age (P = .13) and adverse AML risk factors
(P = .3). The TBF group had more second remissions and more haploidentical grafts. The donor type included HLA-
identical siblings, unrelated donors, and family haploidentical donors. The 5-year cumulative incidence of nonre-
lapse mortality (NRM) was 19% for BUFLU and 22% for TBF (P = .8), and the 5-year cumulative incidence of relapse
was 30% and 15%, respectively (P = .0004). The 5-year actuarial survival was 51% for BUFLU and 68% for TBF
(P = .002). In a multivariate Cox analysis, after correcting for confounding factors, the use of TBF reduced the risk
of relapse compared with BUFLU (P = .03) and the risk of death (P = .03). In a matched pair analysis of 108 BUFLU
patients matched with 108 TBF patients, with the exclusion of haploidentical grafts, TBF reduced the risk of
relapse (P = .006) and there was a trend for improved survival (P = .07). Superior survival of patients receiving TBF
as compared with BUFLU is due to a reduced risk of relapse, with comparable NRM. The survival advantage is
independent of donor type and AML risk factors.
© 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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The combination of intravenous busulfan and fludarabine
(BUFLU) is considered a standard conditioning regimen for
patients with acute myeloid leukemia (AML) undergoing an
allogeneic transplant (HSCT) in first or second remission [1].
Several retrospective studies have shown relatively low nonre-
lapse mortality (NRM) and encouraging leukemia control with
F. Sora et al. / Biol Blood Marrow Transplant 26 (2020) 698703 699BUFLU [2-6]. Two of these studies [5,6] have compared retro-
spectively BUFLU with the standard combination of busulfan
and cyclophosphamide (BUCY): transplant mortality was
reduced in patients receiving BUFLU, which translated in supe-
rior overall survival [5,6].
A prospective multicenter randomized study, comparing
BUFLU with BUCY in patients with remission AML, has also
been conducted [7]. All patients received full-dose busulfan
(3.2 mg/kg/day £ 4 days), combined with fludarabine 160 mg/
m2 or cyclophosphamide 120 mg/kg. The cumulative incidence
of relapse at 5 years was 38% in both groups (P = .7), and NRM
was reduced in the BUFLU arm [7]. The editorial that accompa-
nied this publication suggested that BUFLU should be consid-
ered the standard conditioning regimen for patients with AML
aged 40 to 65 years [1].
The Spanish group headed by Sanz reported some years ago
the efficacy of a new conditioning regimen in patients grafted
with cord blood units [8]: the combination was a modified
BUFLU, with a reduction of the dose of busulfan (3.2 mg/kg/d
£3 days) but with the addition of thiotepa (10 mg/kg): they
named this regimen thiotepa, busulfan, and fludarabine (TBF)
[8]. In a retrospective Eurocord study, TBF conferred a survival
advantage [9]. Since then, the combination has been largely
used in Europe as a preparative regimen for patients with
hematologic malignancies [10-12]. A retrospective study by
the European Group for Blood and Marrow TransplantationTable 1
Clinical Characteristics of Patients
Characteristic BUFLU
Number of patients 201
Sex (M/F), n 90/111
Age, median (range), yr 53 (17-68)
Donor age, median (range), yr 30 (16-68)
Disease stage, n (%)
CR1 168 (84)
CR2 33 (16)
Adverse risk factors, n
Complex cytogenetics 27
Del7 7
FLT3 ITD 31
Primary induction failure 6
Secondary AML 11
Total patients with adverse factors, n (%) 81 (40)
MRD negative 94 (47)
MRD positive 78 (39)
MRD unknown 28 (14)
Interval diagnosis: HSCT 202 (126-868)
Donor type, n (%)
HLA-identical sibling 78 (39)
Family haploidentical 4 (2)
Matched unrelated 89 (44)
Mismatched unrelated 30 (15)
CMV-positive recipient, n (%) 121 (60)
CMV-negative donor, n (%) 48 (24)
CMV serostatus unknown, n (%) 32 (16)
Cell source, n (%)
Bone marrow 35 (17)
Peripheral blood 166 (83)
Follow-up: median days (range) 467 (5-3122)
Primary induction failure: no CR after 1 course of induction chemotherapy. Secondary
ITD indicates internal tandem duplication; CMV, cytomegalovirus.(EBMT) has compared TBF or BUFLU as a conditioning regimen
for remission AML [13]. Relapse was significantly reduced in
patients receiving TBF, but NRM was significantly increased,
leading to comparable leukemia-free survival [13]. However,
when the authors excluded patients receiving TBF with 4 doses
of busulfan, NRM was still greater for TBF patients, but not sig-
nificantly, whereas relapse remained statistically inferior [13].
Given this background, we sought to test in a real-life set-
ting the role of TBF or BUFLU as a conditioning regimen for
patients with AML grafted in first or second remission. We are
now reporting the results of this multicenter comparison in
454 consecutive patients with AML.
METHODS
Eligibility
This is a retrospective study on patients with AML undergoing an alloge-
neic HSCT between January 2008 and December 2018, aged 18 years or older,
in first or second remission (CR1 or CR2). Secondary AML, treatment-related
AML, and AML with trilineage dysplasia were also included. Excluded were
patients with AML in CR1 or CR2 with European Leukemia Net favorable
genetic abnormalities (14). Nine transplant centers in Italy and 1 center in
Israel contributed all their consecutive patients with AML who had undergone
an allogeneic transplant, using either 1 of the 2 conditioning regimens under
study. We therefore studied 454 consecutive patients with AML grafted in CR1
or CR2 and prepared with either TBF (n = 253) or BUFLU (n = 201).
Patients
Characteristics of patients, donor, disease stage, and transplant are sum-
marized in Table 1. There were no significant differences in patients’ age andTBF P Value
253
130/123 .16
50 (18-72) .13
34 (16-67) .11
183 (73) .007
69 (27)
31
5
26
20
10
92 (36) .3
106 (42) .3
116 (46)
30 (12)
192 (111-2542)
53 (21) <.001
145 (57)
38 (15)
17 (7)
157 (62) .4
66 (26)
30 (12)
195 (77) <.001
58 (23)
551 (5-3073) <.001
AML: AML secondary to previous chemo/radiotherapy.
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karyotype, secondary AML, deletion of chromosome 7, FLT3 internal tandem
duplication, or failure to achieve remission after a first course of induction
chemotherapy. The proportion of patients with AML adverse factors was 40%
for BUFLU and 36% for TBF (P = .3) (Table 1). Minimal residual disease (MRD)
was assessed in each center by multicolor flow cytometry: a cutoff of 0.1%
was taken as a positive MRD and was comparable in both groups.
Donors
Donors included HLA-identical matched siblings (SIBs), unrelated donors
(UDs), and family HLA haploidentical members (HAPLO) (Table 1). A haploi-
dentical related donor (HAPLO) was chosen when a suitable sibling or an
unrelated donor was either temporarily or definitively unavailable; second
remission patients also were more frequently assigned to a HAPLO graft (27%
compared with 16% CR2 patients receiving UD grafts). The proportion of
HAPLO donors was higher in the TBF group (Table 1). Cytomegalovirus seros-
tatus is outlined in Table 1.
HLA Typing
SIB donors were HLA genotypically matched with their recipient. UDs
were matched at 4 loci (A, B, C, DRB1) in high-resolution HLA typing in 127
patients and mismatched at 1 locus (7/8) in 47 patients (Table 1).
Follow-up
The median follow-up was 467 days (5 to 3122) for BUFLU and 551 days
(5 to 3073) for TBF (Table 1).
Study
The studywas approved by the Institutional Review Board of the Institute of
Hematology, Gemelli Hospital (March 18, 2019). All patients and donors pro-
vided written informed consent for registration and distribution of anonymous
clinical data for research purposes at the national and international level.
Conditioning Regimens
There were 2 conditioning regimens.
BUFLU
Intravenous busulfan 3.2 mg/kg/d (total dose 12.8, mg/kg), combined with
fludarabine 40 mg/m2/d from day 6 through day 3 (total dose 160 mg/m2),
was the conditioning regimen for all 201 patients, independent of age.
TBF
This regimen consisted of thiotepa, busulfan, and fludarabine: thiotepa
5 mg/kg on days 6 and 5 (total 10 mg/kg), plus busulfan 3.2 mg/kg/d (total
dose 9.6 mg/kg) combined with fludarabine 50 mg /m2/d on days 4, 3, and
2 (total dose 150 mg/m2) (TBF3). For patients older than 60 years or for
patients with significant comorbidities, the dose of busulfan in the TBF regi-
men was reduced to 2 days (TBF2) instead of 3 days: 186 patients received
TBF3 and 67 patients received TBF2.
Choice of the Conditioning Regimen
The choice of the conditioning regimen was not predetermined. BUFLU is
considered a standard regimen and was used in many centers as a standard of
care, especially following the prospective Italian BoneMarrow Transplant Group
(GITMO) randomized trial [7]. TBF is a more experimental regimen, initially used
almost exclusively in cord blood and HAPLO grafts [9-12]. Given the encourag-
ing results, it has then gradually been transferred also to SIB and UD grafts and
is now being used increasingly, at least in Italy. The current comparison was
prompted to assess the outcome of BUFLU and TBF in a real-life setting.
Stem Cell Source
On day 0, 230 patients received unmanipulated bone marrow cells, and
224 received granulocyte-colony stimulating factor mobilized peripheral
blood progenitor cells (Table 1).
Graft-versus-Host Disease Prophylaxis
SIB transplants received a conventional cyclosporin (CsA) methotrexate
regimen. Patients grafted from UDs were given CsA and methotrexate with
the addition of rabbit anti-thymocyte globulin (ATG) (Genzyme, Cambridge,
MA) 5 to 7.5 mg/kg.
HAPLO grafts received post-transplant cyclophosphamide 50 mg/kg £2,
CsA, and mycophenolate. Therefore, patients grafted from UDs received the
same graft-versus-host disease (GVHD) prophylaxis, whether prepared with
BUFLU or TBF; the same was true for patients grafted from SIB or HAPLO
donors.
Supportive care
Patients were given supportive care according to local standards of care,
including monitoring, prophylaxis, and treatment of bacterial, viral, and fun-
gal infections.Statistical analysis
The NCCS11 package was used for chi-square tables, descriptive statistics,
actuarial survival, cumulative incidence reports, and multivariate Cox analy-
sis. Variables included in the multivariate analysis on survival, relapse, and
NRM were the following: phase of the disease (CR1 versus CR2), adverse risk
factors (no versus yes), conditioning regimen (BUFLU versus TBF), recipient
age (50 versus >50 years), year of transplant (2015 versus >2015), donor
type (SIB versus HAPLO, SIB versus UD), stem cell source (bone marrow ver-
sus peripheral blood), and ATG used in the conditioning (no versus yes).
When calculating the cumulative incidence of NRM, relapse was the compet-
ing event and vice versa. The log-rank test was used for differences between
survival curves. The Gray test was used for differences between cumulative
incidence curves.
Matched pair analysis
To compare more rigorously the 2 conditioning regimens, a matched pair
analysis was conducted as follows: HAPLO grafts were excluded because all
except 4 had received TBF; 108 TBF patients, grafted from UD or SIB donors,
were matched with 108 BUFLU patients, selected among the 197 BUFLU
patients who had been grafted from UD and SIB donors. Clinical details of the
2 groups are outlined in Supplementary Table S1. The BUFLU and TBF groups
were matched respectively for patient age (48 years for both groups P = .3),
donor age (37 years versus 32 years, P = .2), disease phase (CR1 80% versus
79%, P = .8), adverse risk factors (33% versus 31%, P = .7), donor type (unre-
lated 55% versus 54%, P = .8), use of ATG (55% versus 54%, P = .8), and median
follow up (1.1 versus 1.3 years, P = .6). There were more peripheral blood
grafts in the BUFLU group (72% versus 49%, P = .01).
RESULTS
Engraftment and GVHD
The median time to a neutrophil count of 0.5 £ 109/L was
15 days (range, 10 to 42) for BUFLU and 17 days (range, 10 to
64) for TBF (P = .001); graft failure was reported in 1 patient
(TBF) as a cause of death.
The risk of grade II to IV acute GVHD was 22% (BUFLU) ver-
sus 19% (TBF) (P = .5); the risk of moderate to severe chronic
GVHD was 22% versus 16%, respectively (P = .2).
Chimerism
Donor chimerism on day +30 after transplant was available
in 326 patients (129 and 197 for BUFLU and TBF, respectively):
it was 98% (average) (range, 46% to 100%) for BUFLU and 97%
for TBF (range, 6% to 100%) (P = .4).
NRM
The 5-year cumulative incidence (CI) of NRM was 19% (95%
confidence interval, 14% to 26%) for BUFLU and 22% (95% confi-
dence interval, 16% to 30%) for TBF (Gray test = 0.8) (Supple-
mentary Fig. 1). In univariate analysis, patients over the age of
50 years had higher NRM (hazard ratio [HR], 1.53; P = .06), and
there was a borderline effect also in multivariate analysis (HR,
1.49; P = .08) (Table 2).
Relapse
The 5-year CI of relapse was 30% (95% confidence interval,
23% to 38%) for BUFLU and 15% (95% confidence interval, 10%
to 21%) for TBF (Gray’s test P = .0004) (Fig. 1A). At 8 years, the
CI of relapse was respectively 30% versus 17%. In univariate
analysis, factors predicting relapse were the conditioning regi-
men (HR, 0.44; P = .0002) and adverse AML risk factors (HR,
1.64; P = .02) (Table 2). In multivariate analysis, the use of TBF
(HR, 0.53; P = .03) and AML risk factors (HR, 1.51; P = .05)
remained independent predictive variables (Table 2).
When selecting only TBF patients, the CI of relapse at 5
years was 14% for HAPLO and 16% for other donor types (sib-
ling and unrelated) (P = .8).
Survival
The 5-year actuarial survival of the entire group of 454
patients was 59% (95% confidence interval, 53% to 64%); it was
Table 2
Univariate and Multivariate Analysis
Univariate Multivariate
Characteristic Baseline Value Compared Value HR P HR P
NON RELAPSE MORTALITY
Phase CR1 CR2 1.01 .9 1.16 .5
Adverse risk No Yes 0.91 .7 0.91 .6
Regimen BUFLU TBF 0.89 .6 0.98 .9
Recipient age 50 >50 1.53 .06 1.49 .08
Year of treatment 2015 >2015 1.01 .9 0.97 .5
Donor SIB HAPLO 1.17 .5 1.68 .2
UD 1.25 .4 1.22 .4
Cell source BM PB 1.29 .2 1.25 .6
ATG No Yes 1.10 .5 1.01 .9
RELAPSE
Phase CR1 CR2 0.9 .8 9.3 .08
Adverse risk No Yes 1.64 .02 1.51 .05
Regimen BUFLU TBF 0.44 .0002 0.53 .03
Recipient age 50 >50 1.23 .3 1.14 .5
Year of treatment 2015 >2015 0.7 .2 0.95 .8
Donor SIB HAPLO 0.58 .07 0.86 .7
UD 1.15 .5 1.51 .5
Cell source BM PB 1.19 .3 0.92 .7
ATG No Yes 1.50 .05 1.15 .5
SURVIVAL
Phase CR1 CR2 0.9 .9 1.15 .4
Adverse risk No Yes 1.19 .2 1.10 .3
Regimen BUFLU TBF 0.56 .0008 0.62 .03
Recipient age 50 >50 1.38 .05 1.39 .04
Year of treatment 2015 >2015 0.89 .5 1.01 .9
Donor SIB HAPLO 0.84 .3 1.27 .4
UD 1.17 .4 1.05 .8
Cell source BM PB 1.46 .09 1.20 .4
ATG No Yes 1.31 .09 1.01 .7
Abbreviations as in Table 1.
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TBF (95% confidence interval, 60% to 76%), P = .002 (Fig. 1B). The
actuarial survival at 8 years was respectively 48% versus 62%.
In univariate analysis, factors predicting survival were the
conditioning regimen, with an HR of 0.56 for TBF versus BUFLU
(P = .0008). In multivariate analysis, after correcting for AML riskFigure 1. Cumulative incidence of relapse (a) and survivafactors, year of transplant, disease phase, stem cell source, the
use of ATG, and donor type, TBF remained a significant positive
predictor of survival, with an HR of 0.62 (P = .03), whereas the
patient age over 50 years remained a significant negative predic-
tor (HR, 1.39; P = .04) (Table 2). When selecting patients receiving
only TBF, we found no differences in survival comparing HAPLOl (b) for patients, with AML receiving TBF or BUFLU.
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P = .2) (Supplementary Fig. S2). The survival advantage of TBF
over BUFLU was seen in patients under the age of 50 years (70%
versus 51%, P = .02) and in patients aged 50 years or above (67%
versus 50%, P = .07) (Supplementary Fig. S3).
TBF3 compared with TBF2
We then compared patients receiving 3 days of busulfan
(TBF3) (n = 186) with patients receiving 2 days of busulfan
(TBF2) (n = 67): the median age was 46 years (18 to 61) for
TBF3 and 61 years (18 to 70) for TBF2 (P < .00001), the propor-
tion of HAPLO grafts was respectively 76% versus 50%
(P = .001), and the proportion of patients with AML CR2 was
26% versus 28% (P = .8) and with AML adverse factors 38% ver-
sus 27% (P = .08). The median follow-up was comparable (467
versus 547 days) (P = .8). The cumulative incidence of relapse
at 5 years was 15% (95% confidence interval, 10% to 22%) for
TBF3 compared with 14% (95% confidence interval, 6% to 29%)
for the older TBF2 patients (P = .4). The cumulative incidence
of NRM at 5 years was respectively 21% (95% confidence inter-
val, 14% to 31%) versus 25% (95% confidence interval, 15% to
40% (P = .4). The actuarial 5-year survival was 65% versus 68%
(P = .8) (Supplementary Fig. S4).
Causes of death
We recorded 148 deaths, 82 in the BUFLU and 66 in the TBF
group. Leukemia relapse was the most frequent cause of death
in 70 of 454 patients (15%): it was recorded in 46 BUFLU (23%)
and 24 TBF patients (9%) (P = .00005). Transplant-related
causes of death were as follows in the BUFLU and TBF groups,
respectively: GVHD (16 and 11 patients), infections (5 and 18
patients), and other transplant-related causes (15 and 13
patients); one of these was reported as sinusoidal obstruction
syndrome in the BUFLU arm.
Matched pair analysis
The CI of relapse at 5 years, in the matched pair analysis,
with the exclusion of HAPLO grafts, was 33% (95% confidence
interval, 24% to 44%) for 108 BUFLU patients and 17% (95% con-
fidence interval, 9% to 29%) for 108 TBF patients (Gray test
P = .006) (Fig. 2A); the 5-year actuarial survival was 52% for
BUFLU (95% confidence interval, 40% to 63%) and 64% for TBF
(95% confidence interval, 51% to 78%) (P = .07) (Fig. 2B); theFigure 2. Cumulative incidence of relapse (a) and survivNRM was respectively 15% (95% confidence interval, 10% to
25%) and 22% (95% confidence interval, 13% to 36%) (P = .56)
(Gray test P = .5).
In a multivariate Cox analysis, using the same variables as
with the entire population, the use of TBF had a protective
effect on mortality (HR, 0.56; P = .02) and on relapse (HR, 0.31;
P = .0008). There was no effect on NRM (HR, 1.2; P = .56).DISCUSSION
Relapse is a major problem in patients with AML undergo-
ing an allogeneic HSCT [15] and has remained unchanged,
unlike NRM, which has been significantly reduced [16]. Inten-
sification of the preparative regimen is one way to attempt a
better control of leukemia: unfortunately, reduction of leuke-
mia relapse may come with increased NRM. In a prospective
randomized study comparing total body irradiation 12 Gy ver-
sus 15.75 Gy in patients with AML [17], relapse was reduced
from 40% with 12 Gy to 15% with 15.75 Gy, but NRM was
increased from 18% (12 Gy) to 38% (15.75 Gy). The net result
was identical 10-year survival for both 12-Gy and 15.75-Gy
patients [17]. Thus, intensification of the conditioning regimen
usually increases the risk of NRM.
In the present retrospective study, we report a significant
reduction of post-transplant leukemia relapse in patients with
AML in first or second remission receiving TBF as compared
with BUFLU, with no detrimental effect on NRM: this resulted
in improved 5-year survival. The TBF regimen is not really an
intensification as compared with the conventional BUFLU, but
rather a modification: instead of 4 doses of busulfan (in the
BUFLU), the TBF regimen has 3 doses of intravenous busulfan
but combines busulfan with thiotepa, 2 very strong myeloabla-
tive agents, both capable of allowing engraftment in a mis-
matched animal model [18,19]. The combination of the 2
alkylating agents appears to be very effective: this is true also
for the older patients receiving only 2 days of busulfan and
thiotepa. Indeed, we could not find a significant difference in
the risk of relapse or survival when comparing patients receiv-
ing 3 days or 2 days of busulfan, despite the fact that TBF2
patients were 15 years older as compared with TBF3 patients:
this resulted in comparable survival for TBF3 and TBF2, both
superior to BUFLU. This suggests that 2 days of busulfan com-
bined with 2 days of thiotepa delivers enough myeloablation
in patients with AML and is tolerated also in patients up to theal (b) for patients with the matched pair analysis.
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transplant settings [8-13], and we have reported encouraging
results in HAPLO transplants [20].
We are particularly impressed with the low incidence of leu-
kemia relapse with TBF (15%) compared with BUFLU (30%), and
this study, although retrospective, is a large multicenter, multi-
national real-life setting. The difference of relapse is not due to
a poor performance of the BUFLU arm: indeed, in the random-
ized trial of BUFLU versus BUCY for patients with AML in first or
second remission [7], the cumulative incidence of relapse at
5 years in the BUFLU arm was 38%, whereas in this study, it was
30%. We therefore confirm the relapse risk of BUFLU recorded
in the prospective study, and we report a significantly inferior
relapse risk with the TBF regimen, as also confirmed by the
EBMT study [13]. The increased risk of NRM in the EBMT study
for TBF patients, compared with BUFLU patients [13], was possi-
bly due to the inclusion of patients receiving 4 doses of busulfan
in addition to thiotepa and fludarabine.
One important question concerns confounding factors: the
proportion of patients with adverse AML risk factors, such as
complex karyotype, secondary AML, deletion of chromosome 7,
FLT3 internal tandem duplication, or failure to achieve remis-
sion after a first course of induction chemotherapy, was compa-
rable in the BUFLU and TBF arms. In addition, the proportion of
patients with positive MRD, as assessed by multicolor flow
cytometry, was comparable in the 2 groups. There were more
HAPLO transplants in the TBF arm, and this could be a bias,
although the difference in relapse was still there when exclud-
ing HAPLO grafts (30% for BUFLU versus 17% for TBF). However,
to better study the impact of the conditioning regimen, we ran
a matched pair analysis, with the exclusion of HAPLO grafts, on
108 BUFLU versus 108 TBF patients: again, relapse was signifi-
cantly reduced in the TBF group (P = .006), and there was a
trend for improved survival, confirmed in multivariate analysis.
Conversely, when selecting only patients receiving TBF,
there was no difference in relapse between HAPLO and other
donor types.
Survival at 5 years was 68% for TBF, compared with 51% for
BUFLU: again, the difference is not due to poor performance of
the BUFLU arm, because in the randomized BUFLU versus
BUCY study, the 5-year survival in the BUFLU arm was quite
comparable (55%), and that study excluded hypoplastic AML
with additional cytogenetic abnormalities and secondary AML
(7). The survival difference was still there when excluding
HAPLO grafts in the matched pair analysis (52% versus 64%)
(P = .07), which reached statistical significance in the multivar-
iate analysis. Finally, when selecting only TBF patients, the 5-
year survival was absolutely identical for patients receiving a
graft from a HAPLO or another donor. This was confirmed in a
multivariate Cox analysis on survival: after correcting for con-
founding factors, the difference in relapse and survival appears
not due to a difference in donor type or a difference in GVHD
prophylaxis.
In conclusion, the conditioning regimen TBF appears to
reduce the risk of relapse in patients with AML in first or sec-
ond remission undergoing an allogeneic HSCT as compared
with a conventional BUFLU. A prospective randomized trial
comparing TBF and BUFLU in patients with AML is currently
being activated.
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